Dogwood Therapeutics (NASDAQ:DWTX) Trading Down 1.1% – What’s Next?

Dogwood Therapeutics, Inc (NASDAQ:DWTX) shares fell 1.1% during trading on Thursday . The company traded as low as $6.09 and last traded at $6.14. 77,549 shares traded hands during trading, an increase of 283% from the average session volume of 20,266 shares. The stock had previously closed at $6.21.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Dogwood Therapeutics in a research note on Wednesday, October 8th. HC Wainwright upped their target price on shares of Dogwood Therapeutics from $10.00 to $12.00 and gave the company a “buy” rating in a report on Tuesday, September 30th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Dogwood Therapeutics has an average rating of “Hold” and an average price target of $12.00.

Dogwood Therapeutics Stock Down 1.1%

The stock has a fifty day moving average of $6.11 and a two-hundred day moving average of $5.35. The stock has a market cap of $14.06 million, a price-to-earnings ratio of -0.25 and a beta of 1.86.

Dogwood Therapeutics (NASDAQ:DWTX) last released its quarterly earnings data on Thursday, November 6th. The company reported ($8.20) EPS for the quarter, missing the consensus estimate of ($1.23) by ($6.97). Equities research analysts anticipate that Dogwood Therapeutics, Inc will post -6.43 EPS for the current fiscal year.

Dogwood Therapeutics Company Profile

Dogwood Therapeutics, Inc is a development-stage biotechnology company, which engages in developing therapeutics for pain and fatigue illness. Its product includes Halneuron. It focuses on antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID and fibromyalgia.